• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

Pershing Square Capital Management

Valeant, Ackman can’t dodge insider trading case from failed Allergan takeover

November 12, 2015 By Brad Perriello

(Reuters) — A U.S. judge said Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) and activist hedge fund manager William Ackman must face a lawsuit accusing them of insider trading in Allergan (NYSE: AGN) before making an unsuccessful takeover bid for the maker of Botox. In a Nov. 9 decision, U.S. District Judge David Carter in Santa Ana, Calif., […]

Filed Under: Legal News, Wall Street Beat Tagged With: Actavis, Allergan, Insider Trading, Pershing Square Capital Management, Valeant Pharmaceuticals

Shares soar for InVivo after spinal cord study update | Medtech Wall Street news for the week of November 17, 2014

November 20, 2014 By MassDevice Contributors Network Leave a Comment

InVivo shares soar on spinal cord study update

November 13, 2014 by Val Kennedy

Filed Under: News Well, Wall Street Beat Tagged With: Actavis, Allergan, InVivo Therapeutics, National Venture Capital Assn. (NVCA), Pershing Square Capital Management, PricewaterhouseCoopers (PwC), Thomson Reuters, Valeant Pharmaceuticals

MDT prepares $10B worth of bonds to help fund its $43B acquisition of COV | The week in medtech M&A

November 19, 2014 By MassDevice Contributors Network Leave a Comment

Report: Medtronic readies $10B bond flotation for Covidien deal

November 17, 2014 by Brad Perriello

Filed Under: Mergers & Acquisitions, News Well Tagged With: Actavis, Allergan, Covidien, Pershing Square Capital Management, Philips, PricewaterhouseCoopers (PwC), Valeant Pharmaceuticals

Ackman supports Allergan’s $66B sale to Actavis

November 18, 2014 By MassDevice Contributors Network Leave a Comment

Ackman supports Allergan's $66B sale to Actavis

Filed Under: Mergers & Acquisitions, News Well Tagged With: Actavis, Allergan, Pershing Square Capital Management, Valeant Pharmaceuticals

UPDATE: Actavis trumps Valeant with $66B offer for Allergan

November 17, 2014 By Brad Perriello Leave a Comment

UPDATE: Actavis trumps Valeant with $66B offer for Allergan

Filed Under: Mergers & Acquisitions, News Well, Pharmaceutical, Wall Street Beat Tagged With: Actavis, Allergan, Pershing Square Capital Management, Valeant Pharmaceuticals

Source: Allergan near $66B buyout to escape Valeant, Ackman

November 17, 2014 By MassDevice Contributors Network Leave a Comment

Source: Allergan near $66B buyout to escape Valeant, Ackman

Filed Under: Mergers & Acquisitions, News Well, Pharmaceutical Tagged With: Actavis, Allergan, Pershing Square Capital Management, Valeant Pharmaceuticals

Report: Actavis may buy Allergan for at least $60 billion

November 12, 2014 By MassDevice Contributors Network Leave a Comment

Report: Actavis may buy Allergan for at least $60 billion

Filed Under: Mergers & Acquisitions, News Well, Pharmaceutical, Wall Street Beat Tagged With: Actavis, Allergan, Pershing Square Capital Management, Valeant Pharmaceuticals

Medtronic inks package of loans worth more than $16 billion to back its $43 billion acquisition of Covidien | The week in medtech M&A

November 12, 2014 By MassDevice Contributors Network Leave a Comment

Medtronic inks $16B loan package for Covidien buyout

November 10, 2014 by Brad Perriello

Filed Under: Mergers & Acquisitions, News Well Tagged With: Allergan, Covidien, Pershing Square Capital Management, Salix Pharmaceuticals, Tornier Inc., Valeant Pharmaceuticals, wrightmedical, Ximedica LLC

Salix inventory snafu sinks deal with Allergan

November 7, 2014 By MassDevice Contributors Network Leave a Comment

Salix inventory issues sink deal with Allergan

Filed Under: Mergers & Acquisitions, News Well, Pharmaceutical, Wall Street Beat Tagged With: Allergan, Pershing Square Capital Management, Salix Pharmaceuticals, Valeant Pharmaceuticals

Allergan in talks with 3rd-party acquirer

November 6, 2014 By MassDevice Contributors Network Leave a Comment

Allergan in talks with 3rd-party acquirer

Filed Under: Mergers & Acquisitions, News Well, Pharmaceutical Tagged With: Actavis, Allergan, Pershing Square Capital Management, Valeant Pharmaceuticals

Court leaves door open for Ackman’s vote at Allergan meeting

November 4, 2014 By MassDevice Contributors Network Leave a Comment

Court leaves door open for Ackman's vote at Allergan meeting

Ackman (Reuters/Eduardo Munoz).
Click to enlarge.

Filed Under: Mergers & Acquisitions, News Well, Pharmaceutical Tagged With: Allergan, Pershing Square Capital Management, Valeant Pharmaceuticals

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 6
  • Go to Next Page »

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy